The Utility of Oral Polypodium Leucotomos Extract for Dermatologic Diseases: A Systematic Review.

IF 1.5 4区医学 Q3 DERMATOLOGY

Journal of Drugs in Dermatology Pub Date : 2025-04-01 DOI:10.36849/JDD.8410

Melissa P Zundell, Abigail Katz, Milaan Shah, Joshua Burshtein, Darrell Rigel, Danny Zakria

{"title":"The Utility of Oral Polypodium Leucotomos Extract for Dermatologic Diseases: A Systematic Review.","authors":"Melissa P Zundell, Abigail Katz, Milaan Shah, Joshua Burshtein, Darrell Rigel, Danny Zakria","doi":"10.36849/JDD.8410","DOIUrl":null,"url":null,"abstract":"Background: Polypodium leucotomos extract (PLE), a fern plant product with strong anti-inflammatory and immunomodulatory properties, has been employed to reduce photoaging and skin cancer. PLE may also serve as an adjuvant treatment for psoriasis, vitiligo, atopic dermatitis, photodermatoses, and melasma. This systematic review synthesizes the current data on PLE usage to manage dermatological diseases.Methods: This systematic review followed the Agency for Healthcare Research and Quality (AHRQ) Methods Guide for Effectiveness and Comparative Effectiveness Reviews and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA) guidelines. PubMed/MEDLINE, Embase, and Cochrane Library were queried using keywords. Articles were screened for inclusion and subsequently grouped by dermatological condition.Results: Twenty-one of the 152 identified articles met inclusion criteria, including 11 randomized controlled trials and 5 treatment trials. Implicated dermatological conditions were photoaging/skin cancer (9 studies), actinic keratosis (3), photodermatoses (3), melasma (2), vitiligo (3), and atopic dermatitis (1). A thorough article review revealed several potential applications of PLE.Conclusion: PLE exhibits strong therapeutic potential with an encouraging safety profile. It has photoprotective and immunomodulatory properties, underscoring its potential as an adjuvant therapy for multiple dermatological conditions. J Drugs Dermatol. 2025;24(4):346-351. doi:10.36849/JDD.8410R1.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"346-351"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8410","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Polypodium leucotomos extract (PLE), a fern plant product with strong anti-inflammatory and immunomodulatory properties, has been employed to reduce photoaging and skin cancer. PLE may also serve as an adjuvant treatment for psoriasis, vitiligo, atopic dermatitis, photodermatoses, and melasma. This systematic review synthesizes the current data on PLE usage to manage dermatological diseases.

Methods: This systematic review followed the Agency for Healthcare Research and Quality (AHRQ) Methods Guide for Effectiveness and Comparative Effectiveness Reviews and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA) guidelines. PubMed/MEDLINE, Embase, and Cochrane Library were queried using keywords. Articles were screened for inclusion and subsequently grouped by dermatological condition.

Results: Twenty-one of the 152 identified articles met inclusion criteria, including 11 randomized controlled trials and 5 treatment trials. Implicated dermatological conditions were photoaging/skin cancer (9 studies), actinic keratosis (3), photodermatoses (3), melasma (2), vitiligo (3), and atopic dermatitis (1). A thorough article review revealed several potential applications of PLE.

Conclusion: PLE exhibits strong therapeutic potential with an encouraging safety profile. It has photoprotective and immunomodulatory properties, underscoring its potential as an adjuvant therapy for multiple dermatological conditions. J Drugs Dermatol. 2025;24(4):346-351. doi:10.36849/JDD.8410R1.

查看原文本刊更多论文

口服白芨提取物治疗皮肤病的应用综述。

背景：白果多糖提取物（PLE）是一种蕨类植物产品，具有很强的抗炎和免疫调节特性，已被用于减少光老化和皮肤癌。PLE 还可作为牛皮癣、白癜风、特应性皮炎、光敏性皮肤病和黄褐斑的辅助治疗药物。本系统性综述综合了当前使用 PLE 治疗皮肤病的数据：本系统综述遵循美国医疗保健研究与质量局（AHRQ）的《有效性和比较有效性综述方法指南》和《系统综述和元分析首选报告项目》（PRIMSA）指南。使用关键词查询了 PubMed/MEDLINE、Embase 和 Cochrane 图书馆。对纳入的文章进行筛选，然后按皮肤病状况进行分组：在 152 篇已确定的文章中，有 21 篇符合纳入标准，包括 11 项随机对照试验和 5 项治疗试验。涉及的皮肤病包括光老化/皮肤癌（9 项研究）、光化性角化病（3 项）、光敏性皮肤病（3 项）、黄褐斑（2 项）、白癜风（3 项）和特应性皮炎（1 项）。一篇详尽的文章综述揭示了 PLE 的几种潜在应用：结论：PLE 具有强大的治疗潜力和令人鼓舞的安全性。结论：PLE 具有强大的治疗潜力和令人鼓舞的安全性，它具有光保护和免疫调节特性，强调了其作为多种皮肤病辅助疗法的潜力。J Drugs Dermatol.2025;24(4):346-351. doi:10.36849/JDD.8410R1.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drugs in Dermatology DERMATOLOGY-

CiteScore

2.20

自引率

13.30%

发文量

289

审稿时长

3-6 weeks

期刊介绍： The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.